Advancing Alzheimer's disease drug review as a national priority

The aging of the baby boom generation continues to put more Americans at increased risk for Alzheimer's disease (AD). The need for meaningful treatment options to fight the destruction caused by AD has never been greater. This article highlights the pivotal role that the U.S. Food and Drug Administration will play in making the review of emerging AD therapies a national priority and ways that various stakeholders are engaging with regulators to meet the challenges posed by the growing AD epidemic.